Genmab A/S Expands Global Commercial Push for Tivdak and Epkinly

Genmab A/S (GMAB) reported 19% YoY revenue growth and a 56% increase in operating profit in Q2 2025, driven by royalties from DARZALEX and Kasimpta, and strong sales of McKinley and Tivdak. The company has accelerated its late-stage pipeline and intensified commercial efforts for Epkinly and Tivdak globally. Genmab aims to become a fully integrated biotech powerhouse by 2030, leveraging its KYSO antibody platform to deliver transformative therapies.

Genmab A/S (GMAB) reported robust financial results for the second quarter of 2025, with a 19% year-over-year (YoY) revenue growth and a 56% increase in operating profit. The company attributed this strong performance to several key factors, including royalties from DARZALEX and Kasimpta, as well as strong sales of McKinley and Tivdak [1].

The company's revenue growth was driven by the continued success of its existing therapies. DARZALEX, a multiple myeloma treatment, and Kasimpta, a treatment for hemophilia A, contributed significantly to Genmab's revenue. Additionally, the company's McKinley and Tivdak therapies also performed well, contributing to the overall revenue growth [2].

Genmab's operating profit increased by 56% YoY, reflecting the company's ability to manage costs effectively while generating strong revenue. This improvement in operating profit is a positive indicator of the company's financial health and its ability to sustain growth in the future.

The company's strong financial performance was also supported by its accelerating late-stage pipeline and intensified commercial efforts for Epkinly and Tivdak globally. Genmab's KYSO antibody platform is a key driver of its pipeline, enabling the development of transformative therapies. The company's focus on expanding its portfolio and leveraging its platform to deliver innovative treatments is a strategic move that positions Genmab for long-term success [3].

In conclusion, Genmab's Q2 2025 financial results demonstrate the company's strong performance and growth potential. The company's ability to generate significant revenue from its existing therapies, combined with its strategic focus on expanding its pipeline and commercial efforts, positions Genmab as a promising investment opportunity in the biotech sector.

References:
[1] https://stockanalysis.com/stocks/gmab/revenue/
[2] https://www.ainvest.com/news/genmab-rina-game-changer-endometrial-cancer-catalyst-shareholder-2508/
[3] https://finance.yahoo.com/news/genmab-receives-fda-breakthrough-therapy-120000705.html